MedImmune’s CytoGam
Executive Summary
Beginning Phase I/II trials for CMV in AIDS patients. The study of the cytomegalovirus immune globulin product is expected to be completed by September with Phase III efficacy trials projected to begin in autumn. CytoGam is already approved for the prevention of primary CMV in kidney transplant patients and Gaithersburg, Md.-based MedImmune will be seeking expanded labeling through submission of data on the use of the product to prevent CMV in liver transplant patients.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth